Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Feb;45(2):272–281. doi: 10.1038/bjc.1982.43

Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.

D W Siemann
PMCID: PMC2010911  PMID: 6460517

Abstract

The effect of combinations of the conventional chemotherapeutic agent 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and nitroimidazole radiation sensitizers was evaluated in female C3H mice. Tumour response to single-agent or combination therapy was assessed in a tumour growth-delay assay. In the KHT sarcoma the simultaneous addition of misonidazole (MISO) was found to increase significantly the tumour growth delay resulting from CCNU treatment. The observed enhancement ratios (ER) increased with MISO dose, and ranged from 1.3 to 1.9 for sensitizer doses of 0.25-1.0 mg/g. The combination of CCNU and 1.0 or 0.5 mg/g MISO in the RIF-1 tumour or the MT-1 tumour produced ERs of approximately 2.0 and approximately 1.5 respectively. In the KHT sarcoma a series of other nitroimidazole sensitizers, including Ro-05-9963, SR-2555, SR-2508 and metronidazole (METRO), were also evaluated at equimolar doses (5 mmol/kg) in combination with a 20mg/kg dose of CCNU. Unlike MISO, these compounds in general failed to enhance the CCNU cytotoxicity in this tumour model. However, SR-2508 did enhance the response of the RIF-1 tumour to large single doses of CCNU, though not as much as MISO. Normal-tissue toxicity was determined using peripheral white blood cell (WBC) counts 3 days after treatment. CCNU doses of 10-50 mg/kg given either alone or in simultaneous combination with 0.5 or 1.0 mg/g MISO were studied. WBC toxicity increased with CCNU dose, but the addition of MISO at either dose did not significantly enhance this normal-tissue toxicity.

Full text

PDF
272

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T., McMenamin M. G., Schein P. S. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. Cancer Res. 1975 Mar;35(3):761–765. [PubMed] [Google Scholar]
  2. Begg A. C., Fu K. K., Kane L. J., Phillips T. L. Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Cancer Res. 1980 Jan;40(1):145–154. [PubMed] [Google Scholar]
  3. Blackett N. M., Courtenay V. D., Mayer S. M. Differential sensitivity of colony-forming cells of hemopoietic tissue, Lewis lung carcinoma, and B16 melanoma to three nitrosoureas. Cancer Chemother Rep. 1975 Sep-Oct;59(5):929–933. [PubMed] [Google Scholar]
  4. Clement J. J., Gorman M. S., Wodinsky I., Catane R., Johnson R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res. 1980 Nov;40(11):4165–4172. [PubMed] [Google Scholar]
  5. Hill R. P. Combined nitrogen mustard--radiation studies with a mouse tumor. Int J Radiat Oncol Biol Phys. 1979 Sep;5(9):1611–1616. doi: 10.1016/0360-3016(79)90783-1. [DOI] [PubMed] [Google Scholar]
  6. Hill R. P. Radiation-induced changes in the in vivo growth rate of KHT sarcoma cells: implications for the comparison of growth delay and cell survival. Radiat Res. 1980 Jul;83(1):99–108. [PubMed] [Google Scholar]
  7. Hill R. P., Stanley J. A. The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res. 1975 May;35(5):1147–1153. [PubMed] [Google Scholar]
  8. Hilton J., Walker M. D. Hydroxylation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Biochem Pharmacol. 1975 Dec 1;24(23):2153–2158. doi: 10.1016/0006-2952(75)90045-3. [DOI] [PubMed] [Google Scholar]
  9. Ings R. M., Law G. L., Parnell E. W. The metabolism of metronidazole (1-2'-hydroxyethyl-2-methyl-5-nitroimidazole). Biochem Pharmacol. 1966 May;15(5):515–519. doi: 10.1016/0006-2952(66)90017-7. [DOI] [PubMed] [Google Scholar]
  10. Johnston T. P., McCaleb G. S., Montgomery J. A. Synthesis and biologic evaluation of major metabolites of N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea. J Med Chem. 1975 Jun;18(6):634–637. doi: 10.1021/jm00240a026. [DOI] [PubMed] [Google Scholar]
  11. Kallman R. F., Silini G., Van Putten L. M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst. 1967 Sep;39(3):539–549. [PubMed] [Google Scholar]
  12. Law M. P., Hirst D. G., Brown J. M. Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. Br J Cancer. 1981 Aug;44(2):208–218. doi: 10.1038/bjc.1981.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. May H. E., Boose R., Reed D. J. Hydroxylation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by rat liver microsomes. Biochem Biophys Res Commun. 1974 Mar 25;57(2):426–433. doi: 10.1016/0006-291x(74)90948-6. [DOI] [PubMed] [Google Scholar]
  14. McNally N. J., de Ronde J. Radiobiological studies of tumours in situ compared with cell survival. Br J Cancer Suppl. 1980 Apr;4:259–265. [PMC free article] [PubMed] [Google Scholar]
  15. Mulcahy R. T., Siemann D. W., Sutherland R. M. In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU. Br J Cancer. 1981 Jan;43(1):93–99. doi: 10.1038/bjc.1981.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Siemann D. W., Hill R. P., Bush R. S. The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):903–911. doi: 10.1016/0360-3016(77)90188-2. [DOI] [PubMed] [Google Scholar]
  17. Siemann D. W. In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer. 1981 Mar;43(3):367–377. doi: 10.1038/bjc.1981.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Siemann D. W., Sutherland R. M. In vivo tumor response to single and multiple exposures of adriamycin. Eur J Cancer. 1980 Nov;16(11):1433–1440. doi: 10.1016/0014-2964(80)90052-3. [DOI] [PubMed] [Google Scholar]
  19. Stephens T. C., Peacock J. H. Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer. 1977 Sep;36(3):313–321. doi: 10.1038/bjc.1977.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sutherland R. M., Bareham B. J., Reich K. A. Cytotoxicity of hypoxic cell sensitizers in multicell spheroids. Cancer Clin Trials. 1980 Spring;3(1):73–83. [PubMed] [Google Scholar]
  21. Sutherland R. M., Eddy H. A., Bareham B., Reich K., Vanantwerp D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1225–1230. doi: 10.1016/0360-3016(79)90643-6. [DOI] [PubMed] [Google Scholar]
  22. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer. 1980 Dec;42(6):871–880. doi: 10.1038/bjc.1980.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer. 1980 Dec;42(6):861–870. doi: 10.1038/bjc.1980.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Thomson J. E., Rauth A. M. An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. Radiat Res. 1974 May;58(2):262–276. [PubMed] [Google Scholar]
  25. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  26. Twentyman P. R. Experimental chemotherapy studies: intercomparison of assays. Br J Cancer Suppl. 1980 Apr;4:279–287. [PMC free article] [PubMed] [Google Scholar]
  27. Twentyman P. R. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer. 1981 Jun;43(6):745–755. doi: 10.1038/bjc.1981.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wheeler G. P., Johnston T. P., Bowdon B. J., McCaleb G. S., Hill D. L., Montgomery J. A. Comparison of the properties of metabolites of CCNU. Biochem Pharmacol. 1977 Dec 15;26(24):2331–2336. doi: 10.1016/0006-2952(77)90436-1. [DOI] [PubMed] [Google Scholar]
  29. White R. A., Workman P., Brown J. M. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiat Res. 1980 Dec;84(3):542–561. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES